Roberta Fazio
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.
Journal: Journal of the National Cancer Institute
Published: February 19, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2026
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 29, 2025
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 25, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2025
First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
Journal: Current oncology reports
Published: August 23, 2024
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Journal: Expert opinion on pharmacotherapy
Published: April 03, 2024
Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
Journal: Cancers
Published: October 03, 2023
Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.
Journal: Frontiers in immunology
Published: September 03, 2023
Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand?
Journal: International journal of molecular sciences
Published: July 03, 2023
Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.
Journal: Frontiers in oncology
Published: March 20, 2023
Advances in drug treatments for mesothelioma.
Journal: Expert opinion on pharmacotherapy
Published: May 04, 2022
Showing 1-12 of 12
Last Updated: 09/26/2026